Usman Mahmood, Amita Shukla-Dave, Heang-Ping Chan, Karen Drukker, Ravi K Samala, Quan Chen, Daniel Vergara, Hayit Greenspan, Nicholas Petrick, Berkman Sahiner, Zhimin Huo, Ronald M Summers, Kenny H Cha, Georgia Tourassi, Thomas M Deserno, Kevin T Grizzard, Janne J Näppi, Hiroyuki Yoshida, Daniele Regge, Richard Mazurchuk, Kenji Suzuki, Lia Morra, Henkjan Huisman, Samuel G Armato 3rd, Lubomir Hadjiiski
BJR Artif Intell . 2024 Mar 4;1(1):ubae003. doi: 10.1093/bjrai/ubae003. eCollection 2024 Jan.
The adoption of artificial intelligence (AI) tools in medicine poses challenges to existing clinical workflows. This commentary discusses the necessity of context-specific quality assurance (QA), emphasizing the need for robust QA measures with quality control (QC) procedures that encompass (1) acceptance testing (AT) before clinical use, (2) continuous QC monitoring, and (3) adequate user training. The discussion also covers essential components of AT and QA, illustrated with real-world examples. We also highlight what we see as the shared responsibility of manufacturers or vendors, regulators, healthcare systems, medical physicists, and clinicians to enact appropriate testing and oversight to ensure a safe and equitable transformation of medicine through AI.